Y. H. Jang

Efficacy, safety and albuminuria‐reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12‐week, double‐blind randomized study (the GUARD Study)

D. Cha, K. Oh, Sung Gyun Kim, 2017, Diabetes, obesity & metabolism.

The Effect of Vildagliptin on Visfatin in Korean Patients with Type 2 Diabetes: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Prospective Study

Y. Kim, Sang Jin Kim, K. Park, 2015 .